Leber hereditary optic neuropathy (LHON) is a mitochondrial genetic disorder, meaning the mutations responsible for it sit in mitochondrial DNA rather than in the chromosomes found in the cell nucleus. This places LHON outside the familiar categories of dominant or recessive inheritance. Instead, it follows a strictly maternal inheritance pattern: only mothers pass the mutation to their children, and they pass it to every child regardless of sex. About 1 in 50,000 people worldwide are affected.
How Mitochondrial Inheritance Works
Most genetic conditions involve mutations in nuclear DNA, the 23 pairs of chromosomes you inherit from both parents. LHON is different. Mitochondria, the structures inside cells that generate energy, carry their own small loop of DNA. When a sperm fertilizes an egg, virtually all the mitochondria in the resulting embryo come from the egg. The sperm contributes almost none. This means a father who carries an LHON mutation will not pass it to any of his children, while a mother who carries it will pass it to all of hers.
All females with the mutation transmit it to the next generation, even if they never develop symptoms themselves. This creates family trees where the condition can appear in every generation on the maternal side but never jumps from father to child.
The Mutations Behind LHON
Three specific point mutations in mitochondrial DNA account for roughly 90% of LHON cases. The most common, found in 60% to 70% of affected individuals of northern European descent and about 90% of those with Asian ancestry, sits in a gene called MT-ND4. A second mutation in MT-ND6 is especially prevalent among French Canadians due to a founder effect, where a small ancestral population carried the variant and passed it widely through descendants. The third occurs in MT-ND1. All three genes encode parts of the same molecular machine: complex I of the mitochondrial respiratory chain, the first step in converting nutrients into usable cellular energy.
Why These Mutations Damage Vision
Complex I is essential for energy production inside cells. When LHON mutations make it less efficient, cells that demand the most energy are hit hardest. Retinal ganglion cells, the nerve cells at the back of the eye that collect visual information and relay it to the brain through the optic nerve, are among the most energy-hungry cells in the body. The faulty complex I leads to a buildup of damaging molecules (oxidative stress) and an energy shortfall that eventually kills these cells. As they die, the optic nerve wastes away, and central vision deteriorates.
Most Carriers Never Lose Their Vision
One of the most striking features of LHON is its incomplete penetrance. Carrying the mutation does not guarantee you will develop symptoms. A large epidemiological analysis estimated overall penetrance at roughly 12.5%, with about 17.5% of male carriers and 5.4% of female carriers eventually experiencing vision loss. Earlier estimates suggested up to 50% of male carriers would be affected, but more recent population-level data indicate the true risk is considerably lower.
The three-to-one male predominance has prompted researchers to look at hormonal explanations. Estrogen appears to stimulate the creation of new mitochondria, a compensatory mechanism that may shore up energy production in retinal ganglion cells. Supporting this idea, the gap between male and female conversion rates narrows before puberty and after menopause, the two life stages when estrogen levels in females are lowest.
Environmental Triggers That Raise Risk
For carriers, certain lifestyle and environmental factors can tip the balance toward vision loss. Tobacco smoking carries the strongest association. In one study of European LHON families, 93% of male smokers with the mutation experienced vision loss compared with 66% of male nonsmokers. Heavy alcohol consumption also raises the likelihood, though the link is weaker than with smoking.
Other reported triggers include head trauma, industrial toxins, medications that interfere with mitochondrial function (certain antivirals and tuberculosis drugs, for example), and nutritional deficiencies such as low vitamin B12. Carriers are generally advised to avoid smoking and heavy drinking and to be cautious with any medication known to stress mitochondria.
What Vision Loss Looks Like
LHON typically strikes in young adulthood. In one natural history study, the average age at onset was about 34, though roughly a third of patients were under 18 when symptoms began. Vision loss usually starts in one eye as a painless blur in the center of the visual field, then spreads to the second eye within weeks to months. Peripheral vision often remains intact, but the central vision needed for reading, recognizing faces, and driving deteriorates significantly.
During an eye exam in the early phase, doctors may see swelling of the nerve fiber layer around the optic disc, dilated and twisted small blood vessels, and a characteristic absence of dye leakage on imaging that distinguishes LHON from other causes of optic disc swelling. Pupil responses tend to remain relatively preserved, and there is no eye pain. These unusual features sometimes lead to an initial misdiagnosis of a psychological or non-organic visual problem. Over time, the optic disc becomes visibly pale as nerve fibers are lost, particularly in the bundle connecting the center of the retina to the brain.
Diagnosis and Genetic Testing
Because the clinical signs can mimic other optic nerve conditions, genetic testing is the definitive way to confirm LHON. Testing typically starts with a targeted screen for the three common mitochondrial DNA mutations, which together cover about 90% of cases. If those come back negative but suspicion remains high, full sequencing of mitochondrial DNA can identify rarer variants. Carriers in a known family can be identified with the same blood test, even if they have no symptoms.
Treatment Options
Treatment for LHON remains limited. The most studied option is idebenone, a synthetic compound related to coenzyme Q10 that supports the mitochondrial energy chain. In the main clinical trial (called RHODOS), about 30% of people taking idebenone showed a clinically meaningful recovery of vision compared with about 10% on placebo. The difference did not reach statistical significance because the trial was small and short, but clinical experts have estimated that roughly half of treated patients may achieve a better visual outcome than they would without treatment. Larger observational studies have shown modest improvements in visual sharpness over 24 months.
The evidence is encouraging enough that idebenone is used in clinical practice in some countries, particularly when started early after symptom onset. Beyond medication, low-vision rehabilitation and assistive technology help people adapt to the central vision loss that persists in many cases.
How LHON Differs From Other Genetic Eye Conditions
LHON sits in a unique category. Unlike retinitis pigmentosa or other inherited retinal diseases that follow standard dominant, recessive, or X-linked patterns, LHON’s mitochondrial inheritance means it cannot be predicted by the usual rules of Mendelian genetics. A carrier mother will pass the mutation to every child, not just half. The condition affects both sexes, though males are far more likely to develop symptoms. And because mitochondrial DNA is present in hundreds or thousands of copies per cell, the proportion of mutated versus normal copies (called heteroplasmy) can vary between individuals in the same family, adding another layer of unpredictability to who ultimately loses vision.